OR WAIT null SECS
The bacterium that causes the sexually transmitted disease gonorrhea is resistant to multiple standard antibiotics and now threatens to develop resistance against ceftriaxone, which is on the World Health Organization List of Essential Medicines and is the last effective antibiotic against the organism. UNC School of Medicine researchers have identified mutations to the bacterium Neisseria gonnorrhoeae that enable resistance to ceftriaxone that could lead to the global spread of ceftriaxone-resistant "superbug" strains.
The findings, published in the journal mBio, provide unique insights into the evolution of drug-resistant gonorrhea that should be useful in monitoring the disease and perhaps in defending against it.
"The first step in stopping a drug-resistant bacterium is figuring out how it becomes resistant to antibiotics that once were able to kill it," said study co-senior author Robert Nicholas, PhD, professor and vice chair of UNC's Department of Pharmacology. "Our results give us clues to how ceftriaxone-resistant gonorrhea is emerging, why this is such a looming problem, and what to focus on to limit it."
Gonorrhea has been a public health problem for hundreds if not thousands of years. In the United States, the number of cases per capita per year rose sharply in the 1960s, then fell just as sharply when the HIV pandemic began. For the past few years the rates of gonorrhea have been rising steeply again. There are more than 800,000 cases per year in the U.S., and worldwide cases are estimated at 80 million annually. About 20,000 people in North Carolina have gonorrhea, according the Centers for Disease Control and Prevention, and the state has the fifth highest rate of infection in the country - about 200 individuals out of 100,000.
If untreatable, complications include infertility, prostate inflammation, scarred and narrowed urethra, testicular and scrotal pain, miscarriage, pelvic inflammatory disease, and inflammation of the bladder.
There is no vaccine for gonorrhea, so antibiotic therapy is the only option for treating infections. However, N. gonorrhoeae has shown a seemingly limitless capacity for evolving resistance to antibiotics. Doctors since the 1980s have had to abandon one first-line therapy after another - penicillin, then tetracycline, then ciprofloxacin, and most recently cefixime. The current standard therapy is a combination of two drugs - the injectable ceftriaxone and oral azithromycin.
N. gonorrhoeae isn't yet widely resistant to ceftriaxone, but two isolates - H041 and F89 - have been shown to be fully resistant to the drug. These cases have raised concerns that ceftriaxone-resistant gonorrhea might soon spread globally, which would make gonorrhea much more difficult to treat and possibly untreatable.
In the study, Nicholas and colleagues, collaborating with the laboratory of Ann E. Jerse, PhD, at the Pentagon's Uniformed Services University in Maryland, showed first that the ceftriaxone-resisting mutations in HO41 and F89 come with a "fitness cost" for the bacterium. In other words, the mutations dramatically impair the bacteria's growth rate.
That was expected. The ceftriaxone-resistance mutations alter the bacterial enzyme that is the target of ceftriaxone, making it harder for the drug to bind to the enzyme but at the same time making it less able for the enzyme to build and repair bacterial cell walls. This fitness cost would be expected to prevent resistant strains from spreading much. The scientists then conducted lab experiments to show that resistant-mutation strains were vastly outcompeted by a standard, non-resistant strain of N. gonorrhoeae, so that the amount of resistant bacteria dwindled rapidly in comparison to the standard strain.
But then the scientists infected mice with an equal mixture of the non-resistant reference strain and the ceftriaxone-resistant, growth-impaired strain. Here's the bad news: Nicholas and colleagues found that some resistant strains quickly developed much higher growth rates and even began to out-compete the fast-growing reference strain.
"That made us suspect that these bacteria had acquired 'compensatory' mutations that improved their growth rate despite the growth-slowing effect of the resistance mutations," Nicholas said.
Scientists will have to sift through the genomes of these lab-evolved superbug strains to identify all the mutations that restore growth and how they do it. This will be the work of multiple studies to come.
But in an initial set of experiments, Nicholas and colleagues zeroed in on one of these mutations that affects a bacterial enzyme called AcnB, known to play an important role in the bacterial energy-production that fuels bacterial growth. The scientists found that the mutant form of the enzyme not only alters N. gonorrhoeae's energy metabolism but also causes extensive changes in the expression of bacterial genes, effectively switching many off and many others on.
"AcnB may have yet-undiscovered functions - beyond its role in energy metabolism - that explain the fitness advantage the enzyme confers when mutated," Nicholas said.
He and his colleagues are working to understand better how mutant AcnB boosts growth of N. gonorrhoeae and what other growth-restoring mutations exist in the lab-evolved superbug strains. At the same time, the researchers are on the lookout for reports of similar dangerous mutations in strains recovered from patients around the world.
The National Institute of Allergy and Infectious Diseases and Uniformed Services University funded this work.